Compare SMID & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | TLSI |
|---|---|---|
| Founded | 1960 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 270.2M |
| IPO Year | 1996 | 2020 |
| Metric | SMID | TLSI |
|---|---|---|
| Price | $24.24 | $4.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 10.0K | ★ 95.6K |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $93,446,000.00 | $45,151,000.00 |
| Revenue This Year | N/A | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | $48.02 | ★ N/A |
| Revenue Growth | 19.03 | ★ 53.41 |
| 52 Week Low | $23.51 | $2.20 |
| 52 Week High | $42.15 | $7.95 |
| Indicator | SMID | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 36.02 | 48.60 |
| Support Level | N/A | $4.70 |
| Resistance Level | $31.47 | $5.58 |
| Average True Range (ATR) | 1.00 | 0.28 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 19.66 | 43.33 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.